NCT04863248View on ClinicalTrials.gov

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
Metastatic Non-Small Cell Lung CancerNSCLCLung Cancer
Interventions
DRUG

Trilaciclib

Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

DRUG

Placebo

Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.

DRUG

Docetaxel

Docetaxel administered IV on Day 1 of each 21-day cycle.

Trial Locations (12)

17325

Gettysburg Cancer Center, Gettysburg

32763

Mid-Florida Hematology Oncology, Orange City

37920

University of Tennessee Medical Center, Knoxville

46526

Indiana University Health Goshen Cancer Center, Goshen

63044

St. Louis Cancer Care, LLP, Bridgeton

77090

Millennium Oncology, Houston

85028

Ironwood Cancer & Research Centers, Phoenix

90067

Valkyrie Clinical Trials, Los Angeles

90602

Innovative Clinical Research Institute - Oncology, Whittier

92270

Desert Hematology Oncology Medical Group, Inc, Rancho Mirage

07932

Summit Medical Group, Florham Park

07739

Regional Cancer Car Associates, LLC, Little Silver

Sponsors
All Listed Sponsors
lead

G1 Therapeutics, Inc.

INDUSTRY

NCT04863248 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | Biotech Hunter | Biotech Hunter